Park Medi World Limited (PARKHOSPS) — Financial Results Announcement
Investor Takeaways
Overall Tone: Neutral based on the numbers only.
Key Financial Highlights
| Metric | Value | YoY Change |
|---|---|---|
| Revenue | ₹3,570.33 Cr | Not available |
| Net Profit | ₹86.06 Cr | Not available |
| EBITDA | Not available | Not available |
| EPS | Not available | |
| OPM | Not available |
What Changed
The filing reports FY2026 revenue of ₹16,793.56 crores, up from ₹6,583.30 crores in FY25, with profit after tax reaching [amount context mismatch] crores versus ₹2,570.74 crores previously. The company recorded total comprehensive income of ₹771.63 crores and ended the year with ₹2,368.50 crores in cash. Strategic hospital acquisitions in January and March 2026 expanded capacity to 610 beds, while IPO proceeds of ₹6,455.79 crores were deployed toward debt reduction and capital expenditure. The auditor confirmed a true and fair view of standalone financials under Ind AS, with no material uncertainties affecting going concern. Current Fundamentals show a Market Cap of ₹10,558.98 Cr.
Peer Comparison
| Company | P/E | ROE | ROCE | Market Cap (₹ Cr) |
|---|---|---|---|---|
| Park Medi World Limited (PARKHOSPS) | Not available | Not available | Not available | 10,558.98 |
| Sun Pharmaceutical Industries Limited (SUNPHARMA) | 41.28 | 15.11% | 20.34% | 4,50,643.09 |
| Divi's Laboratories Limited (DIVISLAB) | 72.41 | 16.56% | 22.09% | 1,79,470.03 |
| Torrent Pharmaceuticals Limited (TORNTPHARM) | 80.06 | N/A% | N/A% | 1,49,108.91 |
Park Medi World Limited's revenue growth trajectory and strategic expansion through hospital acquisitions position it differently from peers with higher P/E ratios but varying profitability metrics.
Risks & Concerns
No specific risks identified in this filing.
Quarterly Trend
Not available
📄 View Original Announcement (PDF)
Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.